<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8" />
    <title>Elisence – Phase 13: Voice & Zero-Typing Engine</title>
    <meta name="viewport" content="width=device-width, initial-scale=1" />

    <!-- Elisa chat widget script -->
    <script defer src="elisa-chat.js"></script>

    <style>
        * {
            box-sizing: border-box;
            margin: 0;
            padding: 0;
        }

        :root {
            --bg-space: radial-gradient(circle at top, #04101f 0%, #02040a 45%, #000000 100%);
            --text-main: #e8f4fc;
            --text-soft: #cbd5f5;
            --text-muted: #94a3b8;
            --accent: #38bdf8;
            --accent-soft: #7dd3fc;
            --card-bg: rgba(15, 23, 42, 0.96);
            --card-border: rgba(56, 189, 248, 0.9);
            --shadow-strong: 0 0 28px rgba(56, 189, 248, 0.9),
                             0 0 52px rgba(15, 23, 42, 0.9);
        }

        body {
            min-height: 100vh;
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Arial, Helvetica, sans-serif;
            background: var(--bg-space);
            color: var(--text-main);
            overflow-x: hidden;
        }

        /* ===== top dot + label ===== */
        .top-dot {
            position: fixed;
            left: 18px;
            top: 18px;
            width: 14px;
            height: 14px;
            border-radius: 50%;
            background: radial-gradient(circle, #34c8ff, #0065ff 65%, #000c28 100%);
            box-shadow: 0 0 18px rgba(0, 170, 255, 0.9);
            z-index: 900;
        }

        .top-dot-label {
            position: fixed;
            left: 40px;
            top: 16px;
            font-size: 14px;
            letter-spacing: 0.22em;
            text-transform: uppercase;
            color: #a9d4ff;
            z-index: 900;
        }

        /* ===== side navigation ===== */
        .side-nav {
            position: fixed;
            right: 32px;
            top: 50%;
            transform: translateY(-50%);
            display: flex;
            flex-direction: column;
            gap: 12px;
            z-index: 999;
        }

        .nav-btn {
            display: block;
            padding: 13px 38px;
            border-radius: 999px;
            text-decoration: none;
            font-size: 14px;
            letter-spacing: 0.14em;
            text-transform: uppercase;
            color: #e3f2ff;
            background: radial-gradient(circle at top,
                rgba(0, 130, 255, 0.45),
                rgba(0, 10, 35, 0.97));
            border: 1px solid rgba(90, 185, 255, 0.9);
            box-shadow:
                0 0 16px rgba(0, 130, 255, 0.95),
                0 0 34px rgba(0, 40, 120, 0.95);
            transition:
                transform 0.2s ease,
                box-shadow 0.2s ease,
                background 0.2s ease,
                padding 0.2s ease;
        }

        .nav-btn:hover {
            transform: translateX(-4px);
            padding-right: 44px;
            box-shadow:
                0 0 22px rgba(0, 190, 255, 1),
                0 0 46px rgba(0, 80, 200, 1);
            background: radial-gradient(circle at top,
                rgba(0, 170, 255, 0.7),
                rgba(0, 25, 80, 1));
        }

        .nav-btn:active {
            transform: translateX(-2px) scale(0.99);
        }

        /* ===== layout wrapper ===== */
        .page-wrapper {
            max-width: 1200px;
            margin: 0 auto;
            padding: 96px 1.8rem 72px 1.8rem;
        }

        .hero-area {
            margin-bottom: 2.4rem;
        }

        .phase-hero-card {
            background: radial-gradient(circle at top left,
                rgba(56, 189, 248, 0.28),
                rgba(15, 23, 42, 0.98));
            border-radius: 26px;
            border: 1px solid var(--card-border);
            box-shadow: var(--shadow-strong);
            padding: 1.6rem 1.8rem;
        }

        .phase-hero-inner {
            display: flex;
            gap: 1.8rem;
            align-items: stretch;
        }

        .phase-hero-logo-box {
            flex: 0 0 290px;
            border-radius: 22px;
            background: radial-gradient(circle at top, #0b1220, #020617);
            display: flex;
            align-items: center;
            justify-content: center;
            padding: 0.75rem;
            box-shadow:
                0 0 24px rgba(15, 23, 42, 0.9),
                0 0 40px rgba(15, 23, 42, 0.9);
        }

        .phase-hero-logo {
            width: 100%;
            max-width: 360px;
            height: auto;
            border-radius: 18px;
            box-shadow: 0 0 28px rgba(15, 23, 42, 0.95);
        }

        .phase-hero-text-box {
            flex: 1;
            display: flex;
            flex-direction: column;
            justify-content: center;
        }

        .phase-label {
            font-size: 0.78rem;
            text-transform: uppercase;
            letter-spacing: 0.18em;
            color: var(--text-muted);
            margin-bottom: 0.3rem;
        }

        .phase-title {
            font-size: 1.9rem;
            letter-spacing: 0.06em;
            text-transform: uppercase;
            color: #f9fafb;
            margin: 0 0 0.35rem 0;
        }

        .phase-subtitle {
            font-size: 0.95rem;
            letter-spacing: 0.14em;
            text-transform: uppercase;
            color: #93c5fd;
            margin-bottom: 0.6rem;
        }

        .phase-lead {
            font-size: 0.98rem;
            color: var(--text-soft);
            margin-bottom: 0.7rem;
        }

        .phase-hero-bullets {
            margin: 0.3rem 0 0 0;
            padding-left: 1.1rem;
            font-size: 0.9rem;
            color: #dbeafe;
        }

        .phase-hero-bullets li {
            margin-bottom: 0.2rem;
        }

        /* ===== detail cards ===== */
        .phase-main {
            max-width: 1100px;
            margin: 0 auto;
        }

        .info-card {
            background: var(--card-bg);
            border-radius: 20px;
            border: 1px solid var(--card-border);
            box-shadow: var(--shadow-strong);
            padding: 1.8rem 1.7rem;
            margin-bottom: 1.8rem;
        }

        .info-card h2 {
            margin-top: 0;
            margin-bottom: 0.85rem;
            font-size: 1.3rem;
            color: var(--accent-soft);
        }

        .info-card h3 {
            margin-top: 1.1rem;
            margin-bottom: 0.4rem;
            font-size: 1.02rem;
            color: #bae6fd;
        }

        .info-card p {
            margin: 0.35rem 0;
            font-size: 0.94rem;
            color: #e5f2ff;
        }

        .info-card ul {
            margin: 0.45rem 0 0.25rem 1.2rem;
            padding-left: 0.3rem;
        }

        .info-card li {
            margin-bottom: 0.32rem;
            font-size: 0.93rem;
        }

        .tagline {
            font-size: 0.94rem;
            color: #93c5fd;
            margin-bottom: 0.45rem;
        }

        .subtle {
            font-size: 0.88rem;
            color: var(--text-muted);
        }

        .highlight {
            border-left: 3px solid var(--accent);
            padding-left: 0.9rem;
            margin-top: 0.4rem;
            font-size: 0.95rem;
            color: var(--text-soft);
        }

        /* ===== responsive ===== */
        @media (max-width: 900px) {
            .page-wrapper {
                padding: 80px 1.2rem 80px 1.2rem;
            }

            .phase-hero-inner {
                flex-direction: column;
            }

            .phase-hero-logo-box {
                flex: 0 0 auto;
            }

            .info-card {
                padding: 1.5rem 1.35rem;
            }

            .side-nav {
                position: fixed;
                right: 50%;
                top: auto;
                bottom: 18px;
                transform: translateX(50%);
                flex-direction: row;
                flex-wrap: wrap;
                justify-content: center;
                gap: 8px;
            }

            .nav-btn {
                padding: 9px 20px;
                font-size: 11px;
                letter-spacing: 0.11em;
            }
        }
    </style>
</head>
<body>

<div class="top-dot"></div>
<div class="top-dot-label">ELISENCE</div>

<nav class="side-nav">
    <a class="nav-btn" href="index.html">Home</a>
    <a class="nav-btn" href="index.html#phases">Phases</a>
    <a class="nav-btn" href="about.html">About</a>
    <a class="nav-btn" href="story.html">Story</a>
    <a class="nav-btn" href="video.html">Videos</a>
    <a class="nav-btn" href="contact.html">Contact</a>
</nav>

<div class="page-wrapper">
    <!-- HERO -->
    <section class="hero-area">
        <div class="phase-hero-card">
            <div class="phase-hero-inner">
                <div class="phase-hero-logo-box">
                    <img src="elisence.png"
                         alt="Elisence – Global Digital Health & Humanity Platform"
                         class="phase-hero-logo">
                </div>
                <div class="phase-hero-text-box">
                    <div class="phase-label">PHASE 13</div>
                    <h1 class="phase-title">Voice &amp; Zero-Typing Engine</h1>
                    <div class="phase-subtitle">
                        HUMAN VOICE INTERFACE · ZERO-TYPING ACCESS · MULTILINGUAL
                    </div>
                    <p class="phase-lead">
                        Phase 13 is the <strong>Voice &amp; Zero-Typing Engine</strong> of Elisence — the
                        primary human interface and accessibility gateway for the entire ecosystem. It enables
                        a true zero-typing experience for elderly users, visually impaired people, busy clinicians
                        and patients in acute distress, while respecting strict regulatory and safety boundaries.
                    </p>
                    <ul class="phase-hero-bullets">
                        <li>Zero-typing access to all major Elisence phases.</li>
                        <li>Tri-layer failure-safe protocol for reliable, safe voice use.</li>
                        <li>Accent- and dialect-aware engine across 5 languages and 4 jurisdictions.</li>
                    </ul>
                </div>
            </div>
        </div>
    </section>

    <!-- DETAIL CARDS -->
    <main class="phase-main">

        <!-- 0. HEADER / CONTEXT -->
        <section class="info-card">
            <h2>0. Phase 13 Executive Context</h2>
            <p>
                <strong>Document Ref:</strong> ELIS-P13-2026-EXEC<br>
                <strong>Role in Ecosystem:</strong> The “Human Interface” of the Elisence platform — how humans
                speak to all 15+ phases, and how those phases safely speak back.
            </p>
            <p>
                <strong>Compliance Framework:</strong>
            </p>
            <ul>
                <li>NHS DCB0129 / 0160 safety mindset.</li>
                <li>FDA CDS-safe positioning (Non-Device CDS).</li>
                <li>EU MDR Class I boundary.</li>
                <li>GCC health privacy and data residency principles.</li>
            </ul>
            <p>
                <strong>Methodology:</strong> BBVP (Build, Backtest, Verify, Prove).<br>
                <strong>Security Model:</strong> Zero-Trust Infrastructure with WORM-style logging, passport-based
                headers (from Phase 11) and strict fail-closed behaviour.
            </p>
        </section>

        <!-- 1. STRATEGIC VALUE PROPOSITION -->
        <section class="info-card">
            <h2>1. The Strategic Value Proposition</h2>
            <p>
                Phase 13 is <strong>not an add-on feature</strong>; it is the primary accessibility gateway
                for Elisence.
            </p>
            <p>
                By enabling a <strong>Zero-Typing environment</strong>, Phase 13 removes friction for:
            </p>
            <ul>
                <li>Elderly users who struggle with keyboards and small screens.</li>
                <li>Visually impaired users who depend on audio for independence.</li>
                <li>Busy clinicians who cannot type during rounds, home visits or emergencies.</li>
                <li>Patients in acute distress, especially in Women’s Health and Diabetes scenarios.</li>
            </ul>
            <p class="subtle">
                Strategically, Phase 13 is how Elisence becomes usable in the real world — in hospital corridors,
                taxis, kitchens, and living rooms — not just at a desk.
            </p>
        </section>

        <!-- 2. RELIABILITY GAP -->
        <section class="info-card">
            <h2>2. Eliminating the “Reliability Gap”</h2>
            <p>
                Generic Voice AI fails when background noise, low confidence, or ambiguous words appear.
                Phase 13 is engineered to <strong>eliminate the reliability gap</strong> through a
                <strong>Tri-Layer Failure-Safe Protocol</strong>:
            </p>

            <h3>Layer 1: Semantic Verification</h3>
            <ul>
                <li>Every Speech-to-Text (STT) output is scored for confidence.</li>
                <li>If STT confidence &lt; <strong>92%</strong>, the engine triggers an automatic
                    <strong>Confirmation Loop</strong>:
                    <ul>
                        <li>Repeats back what it heard (“Did you say…?”).</li>
                        <li>Requests a simple yes/no or short confirmation.</li>
                        <li>Avoids acting on low-confidence guesses.</li>
                    </ul>
                </li>
            </ul>

            <h3>Layer 2: Ambient Noise Suppression</h3>
            <ul>
                <li>Use of localized noise-cancellation models optimised for:
                    <ul>
                        <li>Public transport and street noise.</li>
                        <li>Clinical wards, waiting rooms and pharmacies.</li>
                        <li>Busy homes, kids in the background, TV/radio noise.</li>
                    </ul>
                </li>
                <li>Maintains stable recognition in “High-Chaos” environments.</li>
            </ul>

            <h3>Layer 3: The “Safe-Fail” State</h3>
            <ul>
                <li>If user intent is unrecognized or conflicting, the engine:
                    <ul>
                        <li>Does not guess or improvise.</li>
                        <li>Defaults to pre-approved safety guidance for high-risk phrases.</li>
                        <li>Examples: “If you feel you may be in danger, seek emergency care immediately.”</li>
                    </ul>
                </li>
            </ul>

            <p class="subtle">
                Together, these three layers provide an auditable, regulator-friendly answer to the classic
                “What if Voice AI gets it wrong?” question.
            </p>
        </section>

        <!-- 3. ACCENT & DIALECT MOAT -->
        <section class="info-card">
            <h2>3. The Accent &amp; Dialect Moat</h2>
            <p>
                Global expansion fails when systems cannot understand local accents. Phase 13 is designed to
                solve the <strong>Dialect Problem</strong> that blocks generic AIs in GCC and MENA regions.
            </p>

            <h3>Accent-Aware Hinting (via Passport V1)</h3>
            <ul>
                <li>Leverages Passport V1 (Phase 8 &amp; 11) to pre-load dialect-specific vocabularies at session start.</li>
                <li>For example:
                    <ul>
                        <li>Gulf Arabic vs. Levantine Arabic.</li>
                        <li>Iranian Persian vs. diaspora accents.</li>
                        <li>Regional Turkish, Romanian, and English variants.</li>
                    </ul>
                </li>
                <li>Context-aware language hints embedded in each voice session.</li>
            </ul>

            <h3>Multi-Locale, Multi-Language Engine</h3>
            <ul>
                <li>Native support for:
                    <strong>EN, FA, AR, TR, RO</strong>.
                </li>
                <li>Cultural nuance mapping:
                    <ul>
                        <li>Preferred ways of addressing elders and clinicians.</li>
                        <li>Respectful phrasing for sensitive topics (women’s health, mental health).</li>
                    </ul>
                </li>
            </ul>

            <p class="subtle">
                This dialect-aware approach creates a defensible moat: it is expensive and time-consuming
                for generic global AIs to replicate at healthcare-grade quality.
            </p>
        </section>

        <!-- 4. REGULATORY SAFE-ZONE -->
        <section class="info-card">
            <h2>4. Regulatory “Safe-Zone” Strategy</h2>
            <p>
                Phase 13 is engineered to be <strong>investable</strong> and <strong>low-risk</strong> by holding
                a firm position inside a regulatory “safe-zone”.
            </p>

            <h3>Non-Diagnostic Behaviour</h3>
            <ul>
                <li>Elisa does not diagnose conditions.</li>
                <li>Instead, she identifies <strong>Categories of Concern</strong> such as:
                    <ul>
                        <li>“Potential clinical urgency”.</li>
                        <li>“Please contact your doctor soon” signals.</li>
                    </ul>
                </li>
                <li>Routes risk signals to verified, pre-reviewed safety messages.</li>
            </ul>

            <h3>Non-Prescriptive Engine</h3>
            <ul>
                <li>Never suggests medication names or dosages.</li>
                <li>Never changes treatment plans.</li>
                <li>Always points users back to their own clinicians for medical decisions.</li>
            </ul>

            <h3>Clinical Safety &amp; Classification</h3>
            <ul>
                <li>Aligned with NHS DCB0129 / 0160 safety thinking.</li>
                <li>Designed to remain a “Digital Wellness Companion” or low-risk CDS.</li>
                <li>Avoids the cost, complexity and multi-year delays of Class II Medical Device certification.</li>
            </ul>
        </section>

        <!-- 5. UNIT ECONOMICS & PERFORMANCE -->
        <section class="info-card">
            <h2>5. Unit Economics &amp; Performance</h2>
            <p>
                Phase 13 is designed not only to be clinically safe, but also technically efficient and
                economically viable at national scale.
            </p>

            <h3>Zero-Latency Target</h3>
            <ul>
                <li>Target &lt; <strong>800 ms</strong> Time-to-First-Word (TTFW) for voice responses.</li>
                <li>Achieved using a <strong>Hybrid Edge-Computing</strong> model:
                    <ul>
                        <li>On-device STT for the majority of users.</li>
                        <li>Selective cloud processing for complex cases or low-power devices.</li>
                    </ul>
                </li>
            </ul>

            <h3>Scalability &amp; Cost</h3>
            <ul>
                <li>Approximately <strong>80% of processing</strong> shifted to on-device STT.</li>
                <li>Reduces cloud infrastructure cost per transaction to near zero for most interactions.</li>
                <li>Makes national or multi-country deployments financially realistic.</li>
            </ul>
        </section>

        <!-- 6. BLIND-ASSIST -->
        <section class="info-card">
            <h2>6. Blind-Assist: ESG &amp; Independence</h2>
            <p>
                Phase 13 powers the <strong>“Digital Vision”</strong> module — Elisence’s Blind-Assist capability.
            </p>
            <p>
                By following a <strong>“Descriptive, Not Navigational”</strong> legal framework, the system:
            </p>
            <ul>
                <li>Provides independence for visually impaired users by:
                    <ul>
                        <li>Reading medicine labels aloud.</li>
                        <li>Describing environments and screens.</li>
                        <li>Summarising health information and reminders.</li>
                    </ul>
                </li>
                <li>Avoids navigational liability by:
                    <ul>
                        <li>Not giving “turn left/right” navigation instructions.</li>
                        <li>Not promising safe paths or collision avoidance.</li>
                    </ul>
                </li>
            </ul>
            <p class="subtle">
                Result: a high-impact ESG story — practical independence for blind and low-vision users —
                while maintaining a legally robust risk posture.
            </p>
        </section>

        <!-- 7. INVESTOR ADVISORY -->
        <section class="info-card">
            <h2>7. Investor Advisory: Why Now?</h2>
            <p>
                Phase 13 is the <strong>Control Layer</strong> that standardises how 15 different Elisence
                phases “talk to the world” through voice.
            </p>

            <h3>1) Auditable</h3>
            <ul>
                <li>Every voice intent is logged via WORM (Write Once, Read Many) mechanisms.</li>
                <li>Regulators and ministries can trace:
                    <ul>
                        <li>What was said.</li>
                        <li>How it was interpreted.</li>
                        <li>What safety route was taken.</li>
                    </ul>
                </li>
            </ul>

            <h3>2) Defensible</h3>
            <ul>
                <li>Combination of medical-grade routing, non-diagnostic boundaries and multilingual safety rules.</li>
                <li>Creates a <strong>high moat</strong> that generic LLM-based chatbots cannot easily breach.</li>
            </ul>

            <h3>3) Scalable</h3>
            <ul>
                <li>A single engine governs:
                    <ul>
                        <li>5 major languages (EN / FA / AR / TR / RO).</li>
                        <li>4 major global regulatory zones (NHS, EU, US CDS-safe, GCC).</li>
                        <li>15+ Elisence phases — from Women+ and Diabetes to Environment and Kids+.</li>
                    </ul>
                </li>
            </ul>
        </section>

        <!-- 8. FINAL VERDICT -->
        <section class="info-card">
            <h2>8. Final Verdict</h2>
            <p class="highlight">
                Phase 13 transforms Elisence from a <strong>software tool</strong> into a
                <strong>regulated global infrastructure layer</strong>.
            </p>
            <ul>
                <li>Reduces user friction by up to <strong>90%</strong> via true zero-typing access.</li>
                <li>Maintains the highest standard of clinical and legal safety through:
                    <ul>
                        <li>Tri-layer failure-safe voice handling.</li>
                        <li>Non-diagnostic, non-prescriptive design.</li>
                        <li>Zero-Trust security and WORM logging.</li>
                    </ul>
                </li>
                <li>Locks in a defensible, scalable voice interface that can serve:
                    <ul>
                        <li>Citizens, clinicians and ministries.</li>
                        <li>Multiple regions and languages.</li>
                        <li>All future Elisence phases as they come online.</li>
                    </ul>
                </li>
            </ul>
            <p class="subtle">
                In summary, Phase 13 is how Elisence is heard — safely, clearly and in the user’s own language.
            </p>
        </section>

    </main>
</div>

<!-- Elisa chat widget root -->
<div id="elisa-chat-root"></div>

</body>
</html>
